Quarterly Result27 May 2025, 05:03 pm
Bajaj Healthcare Achieves Significant Progress in Q4 & FY25 with Robust Growth Across Segments
AI Summary
Bajaj Healthcare Limited, a leading manufacturer of APIs, Intermediates and Formulations, announced its audited financial results for the quarter and year ended 31st March 2025. The company reported a strong turnaround in FY25 with robust growth across segments. The key financial highlights include a 15.4% Y-o-Y increase in revenue from operations for Q4FY25 and a 21.2% Y-o-Y increase in revenue from operations for FY25.
Key Highlights
- Acquired Genrx Pharmaceuticals Pvt. Ltd. to enhance in-house formulations manufacturing across allopathic, nutraceutical, and natural products.
- Secured CDMO contracts for 30 APIs with UK/EU partners and received 6 Certificates of Suitability (CEPs) for commercial supplies in regulated markets.
- Centobamate received a favorable SEC recommendation and is awaiting final approval from the DCGI.
- Magnesium L-Threonate (Magtein) is slated for launch next quarter.
- Appointed Mr. Rohan Parekh as Chief Financial Officer and KMP.